Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.

about

Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.

Item

http://www.wikidata.org/entity/Q38709303

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rational design, synthesis, an ...... bitors to overcome resistance.

@en

type

Item

label

Rational design, synthesis, an ...... bitors to overcome resistance.

@en

prefLabel

Rational design, synthesis, an ...... bitors to overcome resistance.

@en

P1476

Rational design, synthesis, an ...... bitors to overcome resistance.

@en

P2093

Chunqi Duan

http://www.w3.org/2001/XMLSchema#string

Gaoyuan Zhu

http://www.w3.org/2001/XMLSchema#string

Lu Wang

http://www.w3.org/2001/XMLSchema#string

Qing Zhang

http://www.w3.org/2001/XMLSchema#string

Tao Lu

http://www.w3.org/2001/XMLSchema#string

Weifang Tang

http://www.w3.org/2001/XMLSchema#string

Yanmin Zhang

http://www.w3.org/2001/XMLSchema#string

Yujun Zhou

http://www.w3.org/2001/XMLSchema#string

Zhimin Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties

Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

P304

3455-3465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1039/C7OB00518K

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28368067

http://www.w3.org/2001/XMLSchema#string